Myelodysplastic Syndrome (MDS)

Intermediate and/or High Risk

Newly diagnosed

IRB# 16867
Abbvie 531 phase 1b venetoclax + azacitidine in treatment naïve subjects

IRB# 16964 - FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)

IRB# 15977 - Non Treatment National MDS Study (ECOG/ACRIN)

IRB# 17379 - Novartis Phase 1B PDR001 and/or MBG453 with decitabine

IRB# 18809 - Renal Impairment Study of CPX-351 (Vyxeos)

IRB# 21730 Study coming soon

Relapsed/ refractory

IRB# 16984 - Abbvie 522 venetoclax by itself or in combination with azacitidine in relapsed/refractory subjects

IRB# 16964 - FORMA phase 1/1b of FT-2102 as single agent and in combination with azacitidine (IDH1 mutation)

IRB# 19290 - Ph 1b Dose-escalation of PLX2853

IRB# 17379 - Novartis Phase 1B PDR001 and/or MBG453 with decitabine

IRB# 18809 - Renal Impairment Study of CPX-351 (Vyxeos)

IRB# 17577 - AZD5991 Monotherapy and in Combination with Venetoclax

IRB# 21165 Study coming soon

Cross Disease Trial

Cross Disease Trial - IRB# 19992 - EAY131 (MATCH)

Lower Risk

IRB# 19978
Phase 1-2 Study of ASTX727 Low Dose Extended Schedule in Subjects with Lower Risk MDS

7/14/2020

http://www.ohsu.edu/research/rda/so/knight.php